To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes
coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging
Subjects who are unwilling or unable to provide informed consent.
Acute coronary syndrome within 12 months before inclusion
Severe chronic heart failure (NYHA IV)
Stroke within 6 months before inclusion
Hospitalized or outpatients with confirmed chronic coronary syndromes
Cohort
Prospective
Antiplatelet Drug
Drugsingle or dual antiplatelets, triple antithrombotic therapy
composite of major adverse cardiovascular events (MACE)
stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cardiac death
composite of any bleeding events
major, clinically relevant nonmajor, minor (BARC, ISTH)
Severity of peripheral atherosclerosis
Assessment will be performed with the use of duplex scanning
Mutations in following genes
CYP2C19\*, ABCB1
Click on the lead sponsor to view all of their trials.
